http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1015618-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6506cf133be42545d51d1490056f6af |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-52 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-90 |
| filingDate | 1963-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1966-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1015618-A |
| titleOfInvention | Glutarimide therapeutic compositions |
| abstract | The invention comprises compounds of the general formula <FORM:1015618/C2/1> wherein R1 is an alkyl group having more than 1 and less than 10 carbon atoms; R2 is an alkyl group of more than 3 and less than 10 carbon atoms, a phenyl or a benzyl group; R3 is a hydrogen atom, an alkyl or alkenyl group having less than 10 carbon atoms, a phenyl, benzyl or phenylethyl group; R4 is a hydrogen atom, a methyl, ethyl or n-propyl group or R1 and R2 may together form a ring provided by a group -(CH2)4-, -(CH2)5-, -(CH2)4CH-(CH3)- or -(CH2)6- and compounds of the formula <FORM:1015618/C2/2> wherein R1 is an alkyl group having less than 10 carbon atoms; R2 is an alkyl group of more than 1 and less than 10 carbon atoms, a phenyl or a benzyl group; R3 is a hydrogen atom, an alkyl or alkenyl group of less than 10 carbon atoms, a phenyl, benzyl or phenylethyl group and n is 1, 2 or 3 and the pharmaceutically acceptable metal and ammonium salts of the compounds of the general formulae above. The compounds are prepared by condensing cyanoacetic ester with an appropriate ketone and ammonia or a primary amine, or first forming the alkylidene cyanoacetate from 1 mol. each of ketone and cyanoacetic ester and reacting the alkylidene cyanoacetic ester with a further 1 mol. of cyanoacetic ester and an amine or with cyanoacetamide and sodium ethoxide and optionally alkylating the alpha-position in either of the end-products.ALSO:Pharmaceutical compositions in dosage unit form comprise a carrier and a compound selected from either <FORM:1015618/A5-A6/1> or their pharmaceutically acceptable metal and ammonium salts, wherein R1 is an alkyl group of less than 10 carbon atoms; R2 is an alkyl group of less than 10 carbon atoms, a phenyl or benzyl group; R3 is a hydrogen atom, an alkyl or alkenyl group of less than 10 carbon atoms, a phenyl, benzyl or phenylethyl group; R4 is a hydrogen atom, a methyl, ethyl or propyl group; n is 0, 1, 2 or 3 and in Formula I R1 and R2 may together form a ring provided by a group -(CH2)4CH(CH3)-, or -(CH2)6-. The compositions may in addition to the glutarimide contain another active ingredient such as sedatives (e.g. amylobarbitone) and diuretics (e.g. chlorthiazide). The compositions are useful for treating hypertension, and may be in the form of tablets, capsules, cachets, packaged powder, pills, solutions for parenteral administration, suppositories for rectal administration or suspensions for oral administration. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4839379-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4764640-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8911856-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8911856-A3 |
| priorityDate | 1962-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.